Skip to main content

Table 1 CSF findings in patients with post-COVID MOGAD disease

From: Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19: a case report and a review of the literature

Variables

CSF protein

CSF cell count

CSF lymphocyte %

Low (≤ 45)

High (> 45)

N (%)

p

No (≤ 5)

Yes (> 5)

N (%)

p

≤ 50%

> 50%

N (%)

p

Age

 50+

0 (0)

1 (100)

1 (14.3)

0.4

0 (0)

1 (100)

1 (20)

1

No CSF

No CSF

 

NA

 < 50

4 (67)

2 (33)

6 (85.7)

 

2 (50)

2 (50)

4 (80)

 

3(75)

1(25)

4(100)

 

Gender

 Female

1 (50)

1 (50)

2 (28.6)

1

1 (100)

0 (0)

1 (20)

0.4

1 (100)

0 (0)

1 (25)

1

 Male

3 (60)

2 (40)

5 (71.4)

 

1 (25)

3 (75)

4 (80)

 

2 (67)

1 (33)

3 (75)

 

COVID-19 severitya

 Non-severe

3 (50)

3 (50)

6 (85.7)

1

1 (25)

3 (75)

4 (80)

0.4

2 (67)

1 (33)

3 (75)

1

 Severe

1 (100)

0 (0)

1 (14.3)

 

1 (100)

0 (0)

1 (20)

 

1 (100)

0 (0)

1 (25)

 

Fatality

 Non-fatal

4 (57.1)

3 (42.9)

7 (100)

NA

2 (40)

3 (60)

5 (100)

NA

3 (75)

1 (25)

4 (100)

NA

 Fatal

0

0

0

 

0

0

0

 

0

0

0

 
  1. CSF cerebrospinal fluid, NA not applicable
  2. P values were calculated from Fisher’s exact test. All observations were non-fatal and thus a Fisher’s exact test was not available between fatality and the outcomes of interest
  3. aSeverity based on the IDSA/ATS guidelines